




 Pulmonary arterial hypertension (PAH) leads to decreased functional status, right-sided heart 
failure, and death. 1 Recently studied therapies have 
improved outcomes, yet substantial heterogeneity 
remains in the risk of adverse clinical outcomes and 
the magnitude of the treatment response. 2-4 
 Plasma levels of endothelin (ET)-1 are elevated 
among patients with PAH, contributing to pulmo-
nary vascular remodeling. 5-7 Endothelin receptor 
antagonists (ERAs) were the fi rst oral therapies 
approved by the US Food and Drug Administration 
(FDA) for use in PAH and remain among the most 
commonly used drugs to treat it. Despite their 
effectiveness, experience has shown that certain 
individuals may have a dramatic clinical response to 
ERAs, whereas others may have no response or may 
worsen. 
 Background:  Recently studied therapies for pulmonary arterial hypertension (PAH) have improved 
outcomes among populations of patients, but little is known about which patients are most likely 
to respond to specifi c treatments. Differences in endothelin-1 biology between sexes and between 
whites and blacks may lead to differences in patients’ responses to treatment with endothelin 
receptor antagonists (ERAs). 
 Methods:  We conducted pooled analyses of deidentifi ed, patient-level data from six randomized 
placebo-controlled trials of ERAs submitted to the US Food and Drug Administration to elucidate 
heterogeneity in treatment response. We estimated the interaction between treatment assign-
ment (ERA vs placebo) and sex and between treatment and white or black race in terms of the 
change in 6-min walk distance from baseline to 12 weeks. 
 Results:  Trials included 1,130 participants with a mean age of 49 years; 21% were men, 74% were 
white, and 6% were black. The placebo-adjusted response to ERAs was 29.7 m (95% CI, 3.7-55.7 m) 
greater in women than in men ( P  5 .03). The placebo-adjusted response was 42.2 m for whites 
and  2 1.4 m for blacks, a difference of 43.6 m (95% CI,  2 3.5-90.7 m) ( P  5 .07). Similar results were 
found in sensitivity analyses and in secondary analyses using the outcome of absolute distance 
walked. 
 Conclusions:  Women with PAH obtain greater responses to ERAs than do men, and whites may 
experience a greater treatment benefi t than do blacks. This heterogeneity in treatment-response 
may refl ect pathophysiologic differences between sexes and races or distinct disease phenotypes. 
  CHEST 2012; 141(1):20–26 
 Abbreviations : 6MWD  5 6-min walk distance; ERA  5 endothelin receptor antagonist;  ET  5 endothelin; FDA  5 US Food 
and Drug Administration; PAH  5 pulmonary arterial hypertension; RCT  5 randomized controlled trial; RV  5 right 
ventricular 
 Race and Sex Differences in Response 
to Endothelin Receptor Antagonists for 
Pulmonary Arterial Hypertension 
 Nicole B.  Gabler ,  PhD ,  MHA ;  Benjamin  French ,  PhD ;  Brian L.  Strom ,  MD ,  MPH ; 
 Ziyue  Liu ,  PhD ;  Harold I.  Palevsky ,  MD, FCCP ;  Darren B.  Taichman ,  MD ,  PhD, FCCP ; 
 Steven M.  Kawut ,  MD ,  FCCP ; and  Scott D.  Halpern ,  MD ,  PhD 
For editorial comment see page 4
 There are known biologic differences between 
sexes and among different races in the production 
and handling of ET-1, a potent systemic and pulmo-
nary vasoconstrictor. Men have higher concentra-
tions of circulating ET-1 than do women, 8,9 and men 
exhibit greater ET-mediated coronary vasoconstric-
tion. 10 Blacks with systemic hypertension are known 
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tissue disease, HIV infection/anorexigen use, or congenital heart 
disease), height, weight, baseline laboratory and hemodynamic 
measures, and concurrent medication use. 
 Outcomes 
 The primary outcome of interest was the change in 6MWD 
from baseline to 12 weeks; 6MWD was the primary end point 
in all but one of the trials and was selected for this reason. Base-
line 6MWD was obtained at the time of, or within 2 weeks prior 
to, randomization. 
 In the primary analyses, patients who were missing a 12-week 
6MWD because of study-ending clinical events (n  5 43) were 
assigned a value of 0 m for their 12-week 6MWD assessment. 
This choice was made a priori based on the assumption that 
patients who were too sick to complete the study would also 
be too sick to complete a 6MWD assessment. We also per-
formed sensitivity analyses using 50, 100, 150, or 275 m (the mean 
12-week 6MWD among patients who sustained a clinical event 
but still completed a 12-week 6MWD assessment) as the 12-week 
6MWD. 
 We conducted four secondary analyses. First, we explored 
differences between baseline and the fi nal recorded 6MWD, 
accounting for the fact that some trials lasted longer than 
12 weeks. These analyses produced results similar to those of 
the primary analyses and are not reported. Second, we examined 
differences in the absolute distance walked at 12 weeks, which 
some have considered a better predictor of clinical outcomes. 18 
Third, we repeated our primary analysis in the subset of patients 
with idiopathic PAH. Finally, we compared the proportions of 
patients in each treatment-by-sex and treatment-by-race stra-
tum who sustained clinical events (death, lung transplant, atrial 
septostomy, hospitalization due to worsening PAH, withdrawal 
for worsening right-sided heart failure, or addition of prostacy-
clin analogs or phosphodiesterase inhibitors for PAH). We did 
not consider deterioration in 6MWD in the clinical event defi ni-
tion because this represented our primary outcome variable. 
 Statistical Analysis 
 Participant characteristics were summarized using medians 
and interquartile ranges for continuous variables and percent-
ages for categorical variables. Primary and secondary outcomes 
were analyzed using linear or logistic regression for continuous 
or binary outcomes, respectively. We restricted the sample to 
blacks and whites when analyzing the interaction of treatment 
assignment with race. Separate models including all patients 
were used to estimate all other effects. 
 For the primary outcome, our most basic model included 
treatment (drug or placebo), sex, race, and the treatment-by-
sex or treatment-by-race interaction terms. This model also 
adjusted for PAH diagnosis (idiopathic, connective tissue disease, 
HIV/anorexigen use, or congenital heart disease, entered as indi-
cator variables), baseline 6MWD, patient height, and study. By 
including sex and height in the model, we effectively modeled 
6MWD % predicted without violating statistical assumptions 
regarding ratio values. 19 In addition, a partially adjusted model addi-
tionally included diagnostic category, age, race, and sex. All other 
variables were examined as potential confounders in a third 
model that included any variables that altered the coeffi cient for 
the interaction term by   15%. A similar approach was used to 
model absolute distance walked without adjustment for base-
line walk distance. Achievement of a certain threshold absolute 
walk distance, if prognostically signifi cant, should be indepen-
dent of baseline walk distance. 
 Multiple imputation was used to impute 12-week 6MWD 
for study participants who did not have a study-ending clinical 
event and were missing a 12-week 6MWD value (n  5 45). 20 The 
to have higher plasma levels of ET-1 than do whites 
and a greater increase in ET-1 in response to stress. 11 
Further, blacks with systemic hypertension have a 
greater reduction in BP with ERAs compared with 
that of whites. 12 The low enrollment of men and 
blacks and the relatively small sizes of phase 2 and 
3 trials of ERAs in PAH have until now precluded 
study-wide tests of heterogeneity in treatment 
response. We, therefore, sought to assess whether 
sex and race modifi ed the effects of ERA therapy in 
placebo-controlled trials of ERAs. 
 Materials and Methods 
 Study Population 
 We obtained data on all participants included in the seven 
randomized placebo-controlled trials of ERAs submitted to the 
FDA. These seven clinical trials (Ambrisentan in Pulmonary 
Arterial Hypertension, Randomized, Double-Blind, Placebo-
Controlled, Multicenter, Effi cacy Studies [ARIES]-1; ARIES-2; 
Bosentan: Randomized Trial of Endothelin Receptor Antagonist 
Therapy [BREATHE]-1; BREATHE-2; Sitaxsentan To Relieve 
Impaired Exercise [STRIDE]-1; STRIDE-2; and STRIDE-4) 
examined three agents (ambrisentan, bosentan, and sitaxsentan). 
We subsequently excluded BREATHE-2 because it included 
only 33 patients, did not collect data on several potential con-
founders, and was not a phase 3 trial. Details of the included trials 
are provided elsewhere. 13-17 
 Deidentifi ed individual patient data for all participants were 
provided by the FDA. The included trials reported similar inclu-
sion criteria, variable collection, and outcome assessment at 
12-week follow-up. 
 Exposure 
 Our primary exposure variable was treatment assignment 
(ERA or placebo). Across trials, different agents and doses 
yielded similar improvements in 6-min walk distance (6MWD) 
relative to placebo and were, therefore, analyzed together. Cova-
riates included age, sex, PAH diagnosis (idiopathic, connective 
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diminished when larger values were entered for these 
12-week walk distances. Likewise, analysis of only 
patients with a diagnosis of idiopathic PAH yielded 
similar overall results (e-Table 5), making it less 
likely that unmeasured differences in disease sub-
types between women and men explained the results. 
Treatment with ERAs (vs placebo) did not infl uence 
imputation model included treatment, sex, and race, in addition 
to variables associated with missing 12-week 6MWD: study, 
baseline walk distance, and diagnosis category. Twenty imputed 
data sets were generated to estimate the variability among 
imputed values. All analyses were completed in SAS, version 9.2 
(SAS Institute). 
 The study was approved by the institutional review board of 
the University of Pennsylvania (Review Board No. 4, approval 
811814). All coauthors had access to the study data, take respon-
sibility for the analysis, and had authority over manuscript 
preparation and the decision to submit for publication. 
 Results 
 The six trials included 1,130 patients. The partici-
pants’ mean age was 49 years (range, 12-82), 21% 
were men, 836 (74%) were white, and 65 (6%) were 
black ( Table 1 ). Seven hundred seventy-three patients 
(68%) were randomized to an ERA and 357 (32%) 
to placebo. Forty-three patients (4%) experienced 
study-ending clinical events; an additional 10 patients 
(1%) sustained clinical events but completed their 
12-week 6MWD assessment. Mean baseline walk 
distance was 349 m (SD 87.0 m). Similar hemody-
namic, laboratory, and severity of illness values were 
observed for men and women, and for whites and 
blacks (e-Tables 1, 2). 
 Treatment Response by Sex 
 The placebo-adjusted treatment response (mean 
improvement in those who received ERAs vs pla-
cebo) was 44.1 m among women and 16.7 m among 
men in the base model ( Table 2 ). Thus, treatment 
response was 27.4 m (95% CI, 1.3-53.5 m) greater in 
women than in men. Women allocated to placebo 
showed a decrement in 6MWD that was prevented 
by assignment to ERAs. Men assigned to placebo 
did not show a decrement in 6MWD, but also did 
not show the benefi t observed in women with assign-
ment to ERAs (e-Fig 1). As shown in the partially 
adjusted model in  Table 2 , adjustment for age, race, 
and diagnosis category did not change these results. 
Further adjustment for potential confounding vari-
ables, such as laboratory and hemodynamic values, 
did not change the results (data not shown). 
 Women also demonstrated greater absolute walk 
distances at 12 weeks, with a placebo-adjusted 
6MWD that was 27.5 m (95% CI, -8.3-63.3 m) greater 
than that for men ( Table 3 ). After adjustment for 
confounders, the placebo-adjusted improvement for 
women was 44.9 m (95% CI, 9.2-80.6 m) greater than 
that for men. 
 Results were similar in sensitivity analyses in which 
higher values were used for the 12-week 6MWD 
among patients experiencing interval clinical events 
(e-Tables 3, 4), but the magnitudes of effect sizes 




(n  5 773)
Placebo 
(n  5 357)
Age, y 50 (38-61) 49 (36-60)
Male sex, No. (%) 158 (20) 78 (22)
Race, No. (%)
 Black 45 (6) 20 (6)
 White 577 (75) 259 (73)
 Other a 151 (20) 78 (22)
Height, cm 162 (157-168) 163 (157-168)
Weight, kg 69 (59-82) 70 (59-85)
BMI, kg/m 2 25.6 (22.7-30.2) 26.2 (22.9-30.6)
PAH diagnosis, No. (%)
 Idiopathic a 478 (62) 229 (64)
 Connective tissue disease 216 (28) 86 (24)
 HIV infection/anorexigen use 23 (3) 11 (3)
 Congenital heart disease 54 (7) 30 (8)
New York Heart Association 
  functional class, No. (%)
 I-II a 256 (33) 114 (32)
 III-IV 516 (67) 243 (68)
Baseline hemodynamics
 Mean right atrial 
  pressure, mm Hg
7.5 (5.0-11.5) 7.5 (4.0-12.0)
 Mean pulmonary arterial 
  pressure, mm Hg
50 (40-60) 51 (42-62)
 Cardiac output, L/min 4.2 (3.3-5.2) 4.2 (3.4-5.3)
 Cardiac index, L/min/m 2 2.3 (1.9-2.9) 2.3 (1.9-2.8)
 Pulmonary capillary wedge 
  pressure, mm Hg
9 (7-12) 10 (7-12)
 Pulmonary vascular 
  resistance, Wood units
10.2 (6.7-14.4) 10.0 (7.0-15.0)
Baseline laboratory values
 Albumin, g/dL 4.2 (3.9-4.5) 4.2 (3.9-4.5)
 Creatinine, mg/dL 0.80 (0.71-0.97) 0.80 (0.68-0.97)
 Hemoglobin, g/dL 14.8 (13.4-16.0) 14.5 (13.0-15.8)
 Sodium, mEq/L 140 (138-142) 140 (138-142)
Warfarin use, No. (%) 466 (60) 230 (64)
Baseline 6MWD, m 360 (289-414) 366 (288-416)
Study, No. (%)
 ARIES-1 134 (17) 67 (19)
 ARIES-2 127 (16) 65 (18)
 BREATHE-1 145 (19) 69 (19)
 STRIDE-1 118 (15) 60 (17)
 STRIDE-2 185 (24) 62 (17)
 STRIDE-4 a 64 (8) 34 (10)
Data are presented as median (interquartile range) unless indicated 
otherwise. 6MWD  5 6-min walk distance; ARIES  5 Ambrisentan 
in Pulmonary Arterial Hypertension, Randomized, Double-
Blind, Placebo-Controlled, Multicenter, Effi cacy Studies; 
BREATHE  5 Bosentan: Randomized Trial of Endothelin receptor 
Antagonist Therapy; PAH  5 pulmonary arterial hypertension; 
STRIDE  5 Sitaxsentan To Relieve Impaired Exercise.
 a Reference category for analysis.
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to patients with idiopathic PAH (e-Table 8). There 
were no clinical events among blacks in the placebo 
groups precluding calculation of a race-by-treatment 
interaction. 
 Discussion 
 This study suggests that sex and race may infl u-
ence the response to ERA treatment of PAH. Specif-
ically, we found that women had signifi cantly greater 
responses in terms of change in 6MWD than did 
men. The differences between races did not meet 
the criteria for signifi cance at the 0.05 level, 
although they had large effect estimates and CIs 
that just included the null value. These fi ndings were 
consistent across different parameterizations of 
6MWD, and were unlikely to be due to difference 
in illness severity because of comparable baseline 
hemodynamic and laboratory measures. We also 
found an indication of greater reductions in clinical 
events with ERAs among women and whites, but 
these differential effects were either not statistically 
signifi cant or were unable to be quantifi ed because 
of the low numbers of events. 
the risk of clinical events among men after adjusting 
for study and baseline walk distance (OR  5 1.28; 
95% CI, 0.22-7.49), but signifi cantly reduced the risk 
of clinical events among women (OR  5 0.27; 95% CI, 
0.14-0.55) ( P value for interaction  5 .11). 
 Treatment Response by Race 
 The placebo-adjusted treatment response was 
41.5 m among whites and  2 3.5 m among blacks in 
the base model ( Table 4 ), a treatment response dif-
ference of 45.0 m (95% CI,  2 2.4-92.4 m) (e-Fig 2). 
Results were similar in the models adjusting for 
diagnosis category, age, and sex. Further adjust-
ment for potential confounding variables did not 
change these results. 
 Placebo-adjusted absolute walk distances at 
12 weeks were 41.6 m for whites and 11.1 m for 
blacks, a difference of 30.5 m (95% CI,  2 35.8-96.8 m) 
( Table 5 ). Similar results were found in partially 
adjusted models including age, sex, and diagnostic 
category, but an attenuation of effects was observed 
when including New York Heart Association class in 
fully adjusted models. Results were similar in sensi-
tivity analyses (e-Tables 6, 7) and in analyses restricted 
 Table 2— Change in 6MWD From Baseline to 12-wk Follow-up by Sex 
Model Women (n  5 894) Men (n  5 236) Difference-in-Difference (95% CI)  P Value for Interaction
Base model a 
 Treatment 33.4 18.8 … …
 Placebo  2 10.7 2.1 … …
   (treatment-placebo) 44.1 16.7 27.4 (1.3-53.5) .04
Partially adjusted model b 
 Treatment 35.6 20.3 … …
 Placebo  2 9.7 4.7 … …
   (treatment-placebo) 45.3 15.6 29.7 (3.7-55.7) .03
See Table 1 legend for expansion of abbreviation.
 a Adjusted for study, height, and baseline walk distance.
 b Adjusted for study, height, baseline walk distance, age, race, and diagnosis category; additional regression output provided in e-Table 9.
 Table 3— Absolute Distance Walked at 12-wk Follow-up by Sex 
Model Women (n  5 894) Men (n  5 236) Difference-in-Difference (95% CI)  P Value for Interaction
Base model a 
 Treatment 381.6 378.0 … …
 Placebo 337.6 361.5 … …
   (treatment-placebo) 44.0 16.5 27.5 ( 2 8.3-63.3) .13
Partially adjusted model b 
 Treatment 373.1 370.7 … …
 Placebo 326.0 357.5 … …
   (treatment-placebo) 47.1 13.2 33.9 ( 2 1.0-68.6) .06
Fully adjusted model c 
 Treatment 369.4 362.5 … …
 Placebo 319.5 357.5 … …
   (treatment-placebo) 49.9 5.0 44.9 (9.2-80.6) .01
 a Adjusted for study and height.
 b Adjusted for study, height, age, race, and diagnosis category.
 c Adjusted for study, height, age, race, diagnosis category, cardiac index, and pulmonary capillary wedge pressure; additional regression output 
provided in e-Table 10.
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observed variation between sexes. Finally, it is pos-
sible that these observed differences are due to 
variations in disease expression on 6MWD between 
men and women, and whites and blacks. 
 Blacks have increased levels of circulating ET-1 11,25 
and greater increases in ET-1 in response to stress. 12 
It is possible that these higher ET-1 levels are not 
suffi ciently inhibited by currently available ERAs. 
A possibly reduced treatment response in blacks is 
consistent with literature reporting higher mortality 
among blacks with idiopathic PAH, 26 and with studies 
suggesting that blacks with cardiovascular and pul-
monary illnesses often have worse outcomes than do 
whites. 27-30 
 The identifi cation of treatment-response hetero-
geneity can improve health care. First, pinpointing 
patient characteristics that modify baseline risks for 
adverse events and/or favorable therapeutic response 
can inform individual treatment decisions. 2,31 Sec-
ond, isolating sources of treatment-response hetero-
geneity can enhance knowledge of the biologic 
mechanisms of disease pathogenesis in PAH. Third, 
recognizing differences in subpopulations with PAH 
could maximize the effi ciency of future randomized 
 Interestingly, women and whites experienced 
deteriorations in 6MWD when assigned to placebo, 
whereas men and blacks did not and even showed 
some improvement on placebo. Women experienced 
greater benefi ts from ERAs compared with men, 
and whites may have benefi tted more than blacks. 
Based on these observations, future studies are 
needed to explore the mechanisms accounting for 
why women and whites may show a greater response 
to ERA treatment. For example, such differences 
might be explained, in part, by known differences in 
estrogen concentrations or signaling 21,22 or in right 
ventricular (RV) contractility 23 between men and 
women. Women with idiopathic PAH have a higher 
RV ejection fraction at baseline, independent of a 
variety of confounders, including pulmonary vas-
cular resistance. 23 Indeed, studies have shown 
improved survival among women with PAH in long-
term treated cohorts. 24 It is possible that RV adap-
tation could allow women to have a greater or more 
rapid response to PAH treatment, while having a 
more severe trajectory without targeted therapy. 
Alternatively, off-target (ie, mechanistically unpre-
dicted) drug effects could account for some of the 
 Table 4— Change in 6MWD From Baseline to 12-wk Follow-up by Race 
Model White (n  5 836) Black (n  5 65) Difference-in-Difference (95% CI)  P Value for Interaction
Base model a 
 Treatment 31.7 14.4 … …
 Placebo  2 9.8 17.9 … …
   (treatment-placebo) 41.5  2 3.5 45.0 ( 2 2.4-92.4) .06
Partially adjusted model b 
 Treatment 32.5 12.0 … …
 Placebo  2 9.7 13.4 … …
   (treatment-placebo) 42.2  2 1.4 43.6 ( 2 3.5-90.7) .07
See Table 1 legend for expansion of abbreviations.
 a Adjusted for study, height, and baseline walk distance.
 b Adjusted for study, height, baseline walk distance, age, sex, and diagnosis category; additional regression output provided in e-Table 11.
 Table 5— Absolute Distance Walked at 12-wk Follow-up by Race 
Model White (n  5 836) Black (n  5 65) Difference-in-Difference (95% CI)  P Value for Interaction
Base model a 
 Treatment 384.1 368.0 … …
 Placebo 342.5 356.9 … …
   (treatment-placebo) 41.6 11.1 30.5 ( 2 35.8-96.8) .37
Partially adjusted model b 
 Treatment 387.0 360.0 … …
 Placebo 344.2 344.9 … …
   (treatment-placebo) 42.8 15.1 27.7 ( 2 36.0-91.4) .39
Fully adjusted model c 
 Treatment 398.7 379.5 … …
 Placebo 357.1 351.9 … …
   (treatment-placebo) 41.6 27.6 14.0 ( 2 47.8-75.8) .66
 a Adjusted for study and height.
 b Adjusted for study, height, age, sex, and diagnosis category.
 c Adjusted for study, height, age, sex, diagnosis category, and New York Heart Association class; additional regression output provided in e-Table 12.
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both sex and race; however, the results for race 
were not statistically signifi cant at the  P  , .05 level. 
The identifi cation of “white” and “black” was not 
uniform in the RCTs included in our study, and such 
misclassifi cation would tend to bias results toward 
the null. We were unable to control for site differ-
ences within each study because of the low number 
of participants at each site. Finally, although our 
study was limited to the trials submitted to the FDA 
for drug approval, these are the precise studies upon 
which ERA treatment recommendations are made 
by the FDA. 
 Conclusions 
 In conclusion, our results indicate that women with 
PAH derive greater treatment responses to ERAs 
than do men. Whites with PAH may also have better 
responses than do blacks. Further studies are needed 
to determine whether these differences are attrib-
utable to heterogeneous responses to ERAs specifi -
cally or to more generalized differences in baseline 
risks for clinical deterioration among groups defi ned 
by race and sex. 
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